What tesamorelin changed for people in the studies
Researchers wanted a brain hormone to last longer in blood. Researchers measured deep abdominal fat, liver fat, and several blood results, with firm limits.
The main tesamorelin results
Tesamorelin’s makers lengthened the time a natural brain hormone could stay in blood, and later large studies found smaller areas of deep belly fat in people receiving HIV care. The 2026 review also showed a drop in liver fat. Most of the proof still concerns those people.
Here are the limits that matter to your own case. The deep fat began returning after the drug stopped. A large weight-loss trial still hasn’t been done in people who don’t have HIV. I’d keep both limits beside any claim you hear about your own health.
How tesamorelin changes growth hormones
Tesamorelin reaches the pituitary, the pea-size growth gland below your brain [4][7]. The gland then releases growth hormone already made by your body in brief rises. A growth-hormone shot can keep the blood level steadier, so the two treatments don’t act the same way.
One study followed 13 healthy men. They received 2 milligrams each day across two weeks. Their growth hormone rose overnight, but the study didn’t show whether they felt any better [4]. A liver-made growth protein rose 181 micrograms per liter [4]. One microgram is a gram split into a million equal parts. Doctors call the protein IGF-1. With no starting number here, the IGF-1 figure only tells you the rise was clear. It doesn’t show a daily-life benefit. The study checked IGF-1 but not fat loss, so the IGF-1 result can’t show that the men lost belly fat.
Another study found that growth hormone still came in bursts [10]. In other work, both a brain hormone and a stomach hormone caused growth hormone to rise in men [8][9]. The two hormones used different routes into the gland. That tells you how the drugs start working, not which drug helps more or has fewer risks.
What tesamorelin did to fat and blood tests
The clearest 26-week trial followed 412 people with HIV. Deep belly fat fell 15.2%. Blood fat fell 50 milligrams per deciliter, and that means in one-tenth of a liter. The liver-made growth protein IGF-1 rose 81% [1]. A 52-week study found the deep fat still 18% below its starting amount [2]. In 2014, scans of 50 adults showed 42 fewer square centimeters of deep fat on one belly scan [3]. That figure is an area on the scan, not fat taken from your body.
Across two Phase 3 trials—late studies that checked the main result and watched for harm—543 people received tesamorelin and 263 received placebo. A person counted as responding when deep fat on one scan fell below 140 square centimeters. More people taking tesamorelin reached that mark. The study’s 95% test said a gap that large would rarely arise by chance, though it couldn’t tell you whether you would respond [13]. People with higher blood fat or a group of sugar-and-heart-risk problems responded more often. White people also responded more often.
In a later scan, the fat left in the belly looked denser. Denser fat is often linked with fat cells that store and use fuel in a healthier way [12]. A clot-related protein called tissue plasminogen activator antigen fell. Adiponectin comes from fat cells and is tied to better handling of sugar and fat; its level rose a little [11]. Both changes were larger when more deep fat was lost. That link points to fat loss as the cause, but it doesn’t prove tesamorelin prevents heart attacks.
What tesamorelin did to deep belly fat
Deep belly fat gave the clearest result. With 2 milligrams a day, it fell 15.2% by 26 weeks. The placebo group rose 5.0% [1]. In 2026, reviewers put five trials together and also found a drop. Their 95% test said the group change was unlikely to be due to chance, though it couldn’t predict one person’s change [14]. The softer fat beneath the skin barely changed. The usual height-and-weight number also moved little [3].
You can trust that finding for the people with HIV who were studied. Researchers haven’t confirmed that result in a large study of ordinary weight loss.
How much deep belly fat tesamorelin changed on one scan
In a 2014 study, one belly scan showed 42 fewer square centimeters of deep fat with tesamorelin (Stanley 2014) [3]. The figure is a flat area visible on a single image; it isn’t fat poured into a container or removed from your body. The soft layer beneath the skin barely changed, and scale weight wasn’t the main result.
These adults had a deep-fat problem caused by HIV care. If your health is different, the study can’t promise the same loss. Deep fat started building again once the drug ended [2].
When tesamorelin changed deep belly fat
The first large study reported that deep abdominal fat had fallen at 26 weeks [1]. A longer study found that the loss held through 52 weeks. The fat remained 18% below its starting amount [2]. Both studies followed people receiving HIV care, so the dates don’t set a timetable for you.
After the drug ended, deep fat began to return. The change wasn’t permanent [2].
What tesamorelin did to fatty liver
A 6-month study followed people receiving HIV care. Tesamorelin cut liver fat by 2.9% more than the comparison treatment [3]. In 2026, reviewers combined five trials and found 4.28% less liver fat overall [14]. Combining the results gave them one broad answer from all five studies.
The change may come from higher growth hormone and IGF-1, a liver-made growth protein, along with smaller areas of fat near the organs and a change in how liver cells use fuel. Fatty liver is not an approved use for the drug. That matters if your liver trouble has another cause.
What liver tests showed with tesamorelin
As growth hormone and IGF-1 rose, liver fat fell 2.9% in one study of people receiving HIV care [3]. The drop seen in deep abdominal fat seems to explain much of the liver change [11].
The safety news was calm. A government review gave tesamorelin a score of E, which means liver injury looked unlikely. Liver blood tests didn’t begin climbing, and no trial injury was traced to the drug [5]. Your own liver trouble may differ from what the studies covered.
How sure the tesamorelin liver finding is
The strongest liver result came from people in HIV care who had extra liver fat. With 2 milligrams a day, liver fat fell 2.9% more than placebo in 2014 [3]. In the 2026 review, researchers combined five trials and found 4.28% less liver fat overall [14].
Every person tested was receiving HIV care. No broad trial has repeated the liver finding in other people. Keep that limit beside any claim you weigh for your health.
What tesamorelin has not proved outside HIV care
The large trials enrolled adults receiving HIV care. One small study included 13 healthy men [4]. Their growth hormone and IGF-1, a liver-made growth protein, rose, but the researchers did not measure fat loss as a health result.
Good trials have yet to show fat loss among people who don’t have HIV. Knowing how the hormones act can’t fill that gap. This use also falls outside the drug’s approval.
What the tesamorelin studies still cannot answer
Keep three limits beside the study results. First, nearly all strong fat-loss proof comes from people whose HIV care changed how their bodies stored fat. No broad study has tested tesamorelin for ordinary weight loss. Knowing how a drug works can’t replace a good human trial.
Second, deep fat began to return within weeks after the last dose [2]. The benefit depended on staying on the drug.
Third, the trials lasted no more than a year. Tesamorelin raises IGF-1, a growth protein, so researchers still need to study cancer risk over many years. No extra cancer warning appeared over 52 weeks, but one year can’t settle a harm that may take longer to appear [2][5].
One study followed one hundred fifty-two older adults for twenty weeks. Tests of planning and self-control improved, but the report here gives no plain score showing how large that gain felt. That finding hasn’t led to an approved use. The clear proof still concerns the change in fat storage caused by HIV care.